FDAnews Drug Daily Bulletin
Pharmaceuticals / Commercial Operations

Pfizer Settles Charges Over Its Copayment Card Program

Oct. 22, 2018
A A

Pfizer has settled allegations that it falsely marketed its copayment coupon program for its Estring, Quillivant and Flector Patch products.

The drugmaker will pay $500,000 in penalties, fees and costs to the State of New York and more than $200,000 in consumer restitution, according to New York Attorney General Barbara Underwood.

Pfizer distributed the copayment coupons — which displayed in large, obvious text that eligible customers would “PAY NO MORE THAN” a certain out-of-pocket amount — to consumers throughout New York “without clearly and conspicuously disclosing” the terms and conditions, Underwood said.

View today's stories